Recently, another licensed-in product from Kexing Biopharm Co., Ltd. (688136.SH) - Liraglutide Injection developed by Tonghua Dongbao Pharmaceutical - has been approved for marketing by Peru's National Drug and Medical Device Agency (DIGEMID).

Recently, Kexing Biopharm Co., Ltd. (688136.SH), in collaboration with Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SH), achieved a significant milestone in its overseas expansion with the blockbuster product Liraglutide Injection.

Recently, Neratinib Maleate Tablets (trade name in Indonesia: Hernera®), an innovative product independently developed by Convalife Pharmaceuticals (Shanghai) Co., Ltd. and licensed to Kexing Biopharm (Stock Code: 688136.SH), has been officially approved by the Indonesian National Agency for Drug and Food Control (BPOM) for marketing via the new drug registration pathway.

Recently, Kexing Biopharm Co., Ltd. (688136.SH) announced that its licensed-in product, a bevacizumab biosimilar, has officially received marketing approval from Bolivia's National Agency of Medicines and Health Technologies (AGEMED).

Recently, Kexing Biopharm (688136.SH) announced the publication of key research findings on its novel antibody fusion protein GB10 project—targeted at anti-choroidal neovascularization diseases—in the renowned international pharmacology journal Biomedicine & Pharmacotherapy.

Recently, Kexing Biopharm (stock code: 688132.SH) has officially received marketing approval from the Georgian Medicines and Pharmaceutical Agency for its licensed-in generic product, Paclitaxel for Injection (Albumin-Bound).

Recently, Kexing Biopharm (stock code: 688136.SH) , in collaboration with Haichang Biotech, which that its Generic Paclitaxel for Injection (Albumin-bound) has received marketing authorization from the Ministry of Public Health (MSP) of Uruguay.

Bevacizumab's First batch Successfully Shipped to Colombia